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Abstract  
Cancer is major disease causing worldwide human death which is related to different epigenetic 
dysregulation. One of the major dysregulation is overexpression of histone deacetylase (HDAC) 
including, HDAC1, HDAC4, HDAC6 and HDAC7. HDAC upregulation leads to histone 
deacetylation at the promoter region of tumor suppressor genes and promote histone 3 lysine 9 
methylation helping in heterochromatinization, leading to abnormal changes in chromatin pattern 
followed by tumorigenesis. In this project novel HDAC inhibitor finding will focus a new light 
on cancer therapy. Our normal diet of fruits and vegetables, contain different bioactive 
compounds like sulforephine, allyl disulfite and butyrate, which have anti-cancerous property. 
Insilco study illustrate that these bioactive compound inhibit HDAC 4, 7 and 6 by binding with 
the active site of HDAC enzyme. This HDAC-bioactive compound complex become inactive 
and fails to remove acetyl group from histone tail which helps in cancer inhibition. Further 
experimental research will confirm the evidence of these novel inhibitors. 
 
 
1. INTRODUCTION 
Epigenetics is the change in the expression of the genes without change in the sequence of the 
DNA. The term ‘epigenetic’ was coined by the developmental biologist, Conrad Hal 
Waddington, in 1942. Cancer is a multi-step process derived from combinational crosstalk 
between genetic alterations and epigenetic influences through various environmental factors 
(Ducasse and Brown 2006; Esteller 2008; Ellis et al., 2009). Environmental exposure to 
nutritional, dietary, chemical and physical factors can alter gene expression and modify 
individual genetic susceptibility through changes in the epigenome (Issa 2008; Suter and 
Aagaard-Tillery 2009; Herceg 2007). 
Epigenetic mechanisms controlling the gene transcription are mainly involved in proliferation, 
differentiation and survival of the cell and are casually linked with malignant development. 
Epigenetic processes like chromatin modifications such as DNA methylation and histone 
acetylation are common targets studied in cancer epigenomics (Herceg 2007; Esteller 2007). In 
cancers it was observed that, half of all tumor suppressor genes are suppressed more due to 
epigenetic, than by genetic, mechanisms (Issa 2008). One hallmark of human cancers is the loss 
of monoacetylation and trimethylation of histone H4 (Fraga et al., 2005) 
Inhibition of HDAC disturbs the cell cycle in G2, allowing cells to prematurely enter the M 
phase and also interfere directly with the mitotic spindle checkpoint. Amazing thing is that, 
HDAC inhibitors appear to activate cell cycle arrest and apoptosis more effectively in cancer 
cells than in non-transformed cells, although the mechanisms are not elucidated.  
Bioactive compounds can destroy the cancer cells by targeting the abnormal pattern of histone 
modification, i.e. HDAC inhibitor Trichostatin A (TSA) and its structural analogs, which are 
potent agents used for cancer therapy. Dietary compounds like sulforaphane (SFN), diallyl 
disulfide (DADS), and butyrate act as weak ligands for HDAC and exhibit HDAC inhibitory 
activity (Marks 2007). 
 Growing evidence suggests that bioactive dietary components impact different epigenetic 
processes like activation of cell survival proteins, reactivation of tumor suppressor genes, and 
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induction of cellular apoptosis in different types of cancer (Landis-Piwowar et al., 2008; Li et 
al., 2010; Paluszczak et al., 2010; Majid et al., 2008).  
There are various types of epigenetic processes are DNA methylation, histone modification, 
RNA interference, all these play central role in gene expression and maintenance of genome.  
1.2  Histone Modification 
Histones are highly alkaline proteins found in nuclei of the eukaryotic cells. This group of 
protein bound to the DNA and forms a structural unit called nucleosome.  
They are the chief protein component of chromatin, around which DNA winds, and mediate gene 
regulation. Histone proteins help in packing of DNA. The unwound DNA in chromosomes 
would be very long without histones (a length to width ratio of more than 10 million to one in 
human DNA) 
Many histone modifications play important roles in epigenetic alterations. Acetylation and 
methylation are the two most important histone modifications that play crucial role in cancer. 
(Davis and Ross 2007; Fraga et al., 2005; Seligson et al.,2005). These two histone modification 
bring on chromatin changes that allow access to the various transcriptional activators and/or 
repressors at gene promoters. Therefore these two histone modification play a crucial role in 
gene regulation and tumorigenesis (Ganesan et al., 2009; Dalvai and Bystricky 2010; Sharma et 
al., 2010). Different types of reversible covalent posttranslational modifications including occur 
in the histone protein including, lysine and arginine methylation, lysine acetylation, lysine 
ubiquitination and sumoylation and serine and threonine phosphorylation, and these 
modifications take place mainly among the histone amino-terminal tails projecting from the 
surface of the nucleosome as well as on the globular core area and regulate fundamental cellular 
processes like transcription, replication, and repair (Kouzarides 2007). Particular histone 
modifications seems to act as programmed “codes” which can be recognize by specific proteins 
to bring about specific downstream events such as transcriptional activation or repression. Here 
our main focus is on the Histone deacetylation which occurs in the lysine by removal of acetyl 
group.    
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Histone modifications are catalyzed by many enzymes such as histone acetyltransferases 
(HATs), histone deacetylases (HDACs). HATs and HDACs add and remove acetyl group to the 
lysine residues present in histones, respectively (Choudhuri et al., 2010). Histone acetylation 
increases chromatin accessibility by neutralizing the DNA–histone interactions which leads in a 
relaxed, open chromatin formation that permits the transcriptional activators to gain access to 
their cognate recognition components and initiate or enhance transcription (Görisch et al., 2005; 
Lafon-Hughes et al., 2008). Histone hypoacetylation at promoter region, caused by either lack of 
HAT activity or increased HDAC activity, consequence in silencing of the tumor suppressor 
gene like p21WAF1/CIP1 in tumorigenesis (Majid et al., 2008; Kikuno et al., 2008). But 
interestingly histone hyperacetylation at certain promoters regions by either higher HAT activity 
or reduced HDAC activity, results in normal repressed gene activation (Acharya et al., 2005; 
Kim et al., 2003).  
1.3    Histone deacetylases  
Histone deacetylases (HDAC) are the class of enzymes which remove acetyl groups from an ε-
N-acetyl lysine amino acid on a histone protein leading to decrease in the space between the 
nucleosome and the DNA that is wrapped around it. Tighter wrapping of the DNA around the 
nucleosome block interaction between transcription factors and DNA lead to transcriptional 
repression (Strahl and Allis 2000). The catalytic  domain  of  HDAC  is  made  by  a  stretch  of  
about  390  amino acids consisting  of  a  set  of  conserved  amino acids  (Finnin et al., 1999). 
The active site comprises of a lightly curved tubular pocket with a wider bottom. Removal of an 
acetyl group takes place through a charge relay system comprising of two neighboring histidine 
residues, two aspartic residues (located more or less 30 amino  acids  from  the  histidines  and  
separated  by  about 6 amino acids) and one tyrosine residue (located approximately 123 amino 
acids downstream from the aspartic residues) (Finnin et al., 1999). An essential constituent of 
this charge-relay system is the presence of a Zn+ + ion as shown in figure 1 and 2. This atom is 
tied to the zinc binding site on the bottom of the pocket. HDAC inhibitors work by moving the 
zinc ion from its original position causing the charge-relay system dysfunctional. TSA, with its 
five-carbon atom linker to the phenyl group and hydroxamic acid group, has the optimal 
conformation to fit into the active site. (Finnin et al., 1999) TSA is one of the most effective 
4 | P a g e  
 
reversible HDAC inhibitors presently
quantity like few nano molar range
  Fig1: Structure of HDAC 7  
  (active site of enzyme under red circle)
1.4   HDAC family 
Histone deacetylases (HDACs) catalyse the removal of acetyl groups from lysine residues
amino termini of histone causing 
al. 2001; Thiagalingam et al.,
According to their homology to yeast
are subdivided into four classes, 
8) are homologous to the yeast 
ubiquitous expression in various human cell lin
HDAC5, HDAC6, HDAC7, 
protein and shuttle between the nucleus and the cytoplasm. The classes IIb HDACs are HDAC6 
and HDAC10 and they are 
domains.  The class III HDACs (SIRT1, 2, 3, 4, 5
Sir2 and require NAD+ for their activity
the cellular redox status. At last the c
under these class. It shows sequence similarity with the catalytic 
 known, with IC50 and SAHA which works 
 (Yoshida et al., 1990). 
  
                  Fig2: Active site of HDAC7
 
chromatin condensation and transcriptional repression
 2003) Till now eighteen HDACs have been identified in humans
, subcellular localization and enzymatic activities 
(Thiagalingam et al., 2003). The classes I HDACs (1, 2, 3 and 
RPD3 protein, generally present in the nucleus and show 
es and tissues. Class II HDACs HDAC
HDAC9 and HDAC10 share homologies wit
generally found in the cytoplasm and contain two deacetylase 
, 6 and 7) are homologues of the yeast protein 
; they regulate gene expression according
lass IV HDACs, HDAC11 is the only enzyme reported 
domain
in very low 
 
 
 from 
 (Roth at 
. 
HDACs 
4, 
h the yeast Hda1 
 to changes in 
 of both class I and II 
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HDACs enzymes but does not have strong enough identity to be placed in either class (Catley et 
al., 2003). 
 
Fig3: Different class of HDACs (Bolden et al., 2006) 
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1.5    HDAC inhibitors 
Histone deacetylase inhibitors (HDACi) are a class of compounds that intervene with the 
function of histone deacetylase by displacing the Zn++. Without Zn++ HDAC cannot recognize 
the acetyle group and unable to remove it from histone leading to euchromatin formation. There 
are a lot of inhibitors but most potent observed so far is Trychostatin (TSA) which is a 
fermentation product of Streptomyces. A large number of HDACi have been purified from 
natural sources or synthetically prepared. 
1.5.1 HDAC inhibitor in the diet 
For more than a decade, there has been substantial concern in the use of naturally occurring 
drugs for the prevention of diseases, including cancers. Vegetables, fruits, Beverages, and other 
elements of the human diet normally contain polyphenols which have been demonstrated in 
many investigations to have chemopreventive and anti-cancer property. (Aggarwal and Shishodia 
2006; Meeran and Katiyar 2008; Yang et al., 2001). Various nutrients, specifically dietary drugs, 
can play a major role in the regulation of both normal and pathological process. Better 
understanding of the regulative role of these nutrients on several molecular targets may help in 
the prevention and treatment of different type of cancers. Several dietary compounds or nutrients 
govern various molecular targets in different type of cancers. Sulforaphane from cruciferous 
vegetables, genistein from soybean, tea polyphenol-catechins from green tea, curcumin from 
turmeric, diallyl disulfide from garlic, resveratrol from grapes, and other bioactive compounds 
like cyanidins from grapes apigenin from parsley, isothiocyanate from cruciferous vegetables, 
baicalein from Indian trumpet and  rosmarinic acid  from rosemary (Meeran et al., 2010). These 
bioactive compounds target various epigenetic targets like HDAC, DNA methyl Transferase etc.  
We mainly focused on the HDAC inhibitors such as sulforaphane, allyl disulfide and butyrate. 
So we performed molecular docking of different HDACs (4, 6, 7) with sulforaphane, diallyl 
dsulfide and butyrate. Comparative study using bioinformatics tool shows that sulforaphane 
show more efficiently inhibiting the HDACs in comparison to diallyl disulfide and butyrate. It 
can be an ultimate dietary drug for cancer prevention. 
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  Fig4: Role of dietary histone deacetylase (HDAC) inhibitors in cancer cell (Meeran et al., 2010 
Semin Cancer Biol. 2007 October ; 17(5): 363–369. doi:10.1016/j.semcancer.2007.04.001.NIH-) 
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2. REVIEW OF LITERATURE 
2.1  Role of HDAC in cancer 
There  are  no  decisive  data  regarding  the  pattern  of  HDAC  expression  in  human cancer, 
but there are a number of studies showing altered expression of different type HDACs in 
different tumor samples. 
Altered regulation of DNA methylation and post-translational histone modifications are 
characteristic hallmarks of human cancers. Fraga et al., 2005 shown that, loss of acetylated 
Lys16 (K16-H4) and trimethylated Lys20 (K20-H4) of histone H4 is a common consequence in 
human cancer that is linked with the hypo-methylation of repetitive sequences in primary tumors 
and human cancer cell. Moreover, they shown the data from a mouse model of multistage skin 
cancer tumorigenesis, indicating that the global loss of monoacetylated and trimethylated forms 
of histone H4 is a crucial event in cancer development and these changes occur early in 
tumorigenesis  
Yasui et al., 2003 observed reduction in histone acetylation is not only involved in introduction 
of tumor genesis but also in tumor invasion and metastasis in gastro intestinal tumors. Santiago 
Ropero and Manel Esteller have reported an increase in expression of HDAC 1 in breast, gastric, 
colon and prostate cancer, over expression of HDAC 2 in cervical, gastric cancer and in 
colorectal carcinoma with loss of APC expression, high levels of HDAC3 in colon cancer and 
HDAC6 expression and breast cancer specimens. 
2.2 Effect of histone deacetylase inhibitors in cancer cell 
It have been reported that HDACi (HDAC inhibitors) disrupt the cell cycle in G2 and allow the 
cells to prematurely enter the M phase, as well as interrupting the mitotic spindle checkpoint. 
HDAC inhibitors appear to initiate cell cycle arrest and apoptosis more specifically in cancer 
cells than in normal cells, the mechanisms for this is still not elucidated. Recent studies have 
implicated the induction of pro-apoptotic genes like TRAIL (TNF-related apoptosis-inducing 
ligand), DR4 (Death Receptor 4) and DR5 (Death Receptor 5) occur only in transformed cells 
(Ungerstedt et al., 2005; Nebbioso et al., 2005). The fundamental epigenetic differences between 
normal and tumour cells could alter the transcriptional response to HDACi. It has been already 
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proved that global hypo-acetylation of histone H4 is a common hallmark of human tumours. 
Alterations in H4 acetylation occur early in the tumorigenic process (Fraga et al., 2005). 
Reestablishment of a normal epigenetic condition by HDACi, or selective induction of tumour-
suppressive genes like TRAIL by HDACi specifically in the context of a neoplastic epigenome’, 
could be clinically beneficial (Bolden et al., 2006).  
Patra et al.,, 2001 to demonstrate that DNMT1 and HDAC1 levels are up-regulated in prostate 
cancer. They reported that HDACs activities were two- to threefold higher in prostate cancer cell 
lines compared to benign prostatic hyperplasia (BPH-1) cell line. 
Activation of either an extrinsic or intrinsic pathway or both of these cell death pathways by all 
the HDAC inhibitor is observed in many cancer models (Rosato et al., 2003). Xu et al.,, 2008 
reported that when the ligands, like Fas or TRAIL bind to their death receptors they activate the 
death-receptor pathway. Without altering the levels of DR4 or DR5 in breast cancer cells MS275 
(entinostat) and SAHA induce TRAIL expression, which was mediated through SP1 and cause 
increase adriamycin cytotoxicity in breast cancer cells  All these consequences resulted in the 
recruitment of an adaptor protein, FADD, and the activation of caspase-8. Stress stimuli by 
chemotherapeutic agents disrupt the mitochondrial membrane, leading to the release of proteins, 
including cytochrome c and SMAC. Apoptosome formation and activation of caspase-9 is 
mediated by Cytochrome c release. Caspases-3, -6, and -7 then cleaved by caspase-8 and 
caspase-9, leading to apoptosis. Mitochondrial disfunction and apoptosis by XIAP down-
regulation increase in ROS generation and JNK1 activation is cause by SAHA and MS275.  (Xu 
et al., 2008) 
Fulada .S shown that, treatment of various cancer cell with HDAC inhibitor like FK228, TSA, 
LBH589 and SAHA show amplification of intrinsic as well as extrinsic apoptotic pathways due 
to decrease in the expression of Bcl-2, Bcl-xL and XIAP, and an increase in the expression of 
pro-apoptotic proteins, such as Bak and Bax, is cause enhance TRAIL-mediated cytotoxicity in 
various type of cancer cells 
2.3 Dietary bioactive compound as HDAC inhibitor 
Phytochemicals or dietary bioactive compounds are non-nutritive elements in the plant which 
possess significant antimutagenic and anticarcinogenic properties. There is a great structural 
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diversity in the phytochemicals
molecular mechanisms. Elucidation
analyze their effects on cancer
Young-Joon Surh, 2003 conduct studies on more than 250 people 
control and cohort studies and observed
more prone to cancer, specially
people who eat about five 
developing cancer)  
The NCI has reported around
cruciferous vegetables (cabbage, broccoli, cauliflower etc.), 
onion and tomatoes etc 
2.3.1 Sulforaphane 
Sulforaphane is an organ sufur 
broccoli, cabbage, cauliflowers etc and exhibits some excellent properties like antidiabetic, 
anticancer and antimicrobial properties in various experimental 
Fig 5: Chemical structure of sulforaphane
2.3.2  Allyl disulfide 
Allyl Disulfide is an organosulfur
water insoluble liquid and has a strong garlic odor
terminating with a carboxylic acid functional group
Fig 6: Chemical Structure of Allyl Disulfide
 structure and activity relationships to deduce their
 of signal transduction pathways is a 
.  
population, including
 that, Those people who eat fewer than two servings are 
 cancers in the digestive and respiratory
servings of fruit and vegetables a day (about
 35 plant-based foods that have anticancer 
turmeric, garlic, soybeans, ginger,
compound, mostly present in cruciferous vegetable like 
models. 
 (wikipwdia.org)
 compound produced in garlic. It is a yellowish
. It matches butyrate in having 
. 
 (wikipwdia.org)
 underlying 
better approach to 
 case 
 tracts as compare to 
 half the risk of 
properties including 
 
 
 
 color 
a spacer 
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2.3.3 Butyrate 
Butyric acid is present
anaerobic fermentation in our body
animal fats 
Fig7: Chemical structure of Butyrate 
Butyrate comprises a short three
enter into the active site of the enzyme and forms a 
 
  
 
 
 
 
 
 
 in butter, Parmesan cheese, and vomit, and 
. It is a fatty acid present in the form of 
. 
(Wikipedia.org)
-carbon spacer attached to a carboxylic acid group, which
bidentate ligand with the zinc
 
is a product of 
esters in plant oils and 
 
 may 
 atom. 
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3. Objective 
 Study of  interaction between bioactive compounds (sulforaphane, allyl disulfide, 
autyrate) as inhibitor and HDAC (4, 6, 7) using Bioinformatics Tools 
 Comparative study among Sulforaphane, butyrate and allyl disulfide as HDAC inhibitor. 
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4. MATERIALS AND METHOD 
The structural details of the following HDACs (4, 6, and 7) proteins present in Homo sapiens 
were obtained from structural database of “Protein Data Bank” (PDB) (http:/ 
/www.rcsb.org/pdb). The structures are conventionally represented by specific 4 letter code of 
pdb id such as 2VQM, 3PHD, 3C0Y for respective proteins mentioned above.  
4.1 Software Required 
 Chimera 
 Swiss Pdb Viewer 
 Hex 
 LIGPLOT+  
 Open Babel 
4.2 Preparation HDAC enzymes of Homo sapiens for docking 
Chimera 
It is a highly extensible program for interactive visualization and analysis of molecular structures 
and related data, including density maps, sequence alignments, docking results, trajectories, 
conformational ensembles and supra-molecular assemblies. High-quality images and animations 
can be generated. Chimera is developed by the Resource for Bio computing, Visualization, and 
Informatics, funded by the National Institutes of Health National Center for Research Resources 
and National Institute of General Medical Sciences  
Protocol 
The non-standard residues in the structural pdb files of HDAC proteins were edited using 
Chimera. The removal of the residues resulted in energetically unstable protein. The proteins 
were stabilized by the process of energy minimization using “Swiss PDB Viewer”. Subsequently 
HDACs (4, 6 and 7) proteins were uploaded to Hex, and polar hydrogen was added to each of 
those HDAC. The charge on Zinc (Zn) ions of the proteins was converted from 0 to +2 by using 
python script. They were saved in pdb format. 
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4.3 Preparation of HDAC enzymes of Homo sapiens inhibitor files 
The 3D structural details of  ligands such as Sulforaphane, allyl disulfide and butyrate were 
downloaded from “Pub Chem” structure data base at NCBI site (ncbi.nlm.nih.gov) and the 
compound id were 5350, 16590, 104775 respectively. All the files were in SDF format. The SDF 
files format was converted to PDB format file using “Open Bable Software”. The ligands in PDB 
format were loaded with Auto Dock. The torsion of the ligands was adjusted based on the total 
number of rotatable bonds. The ligands were saved in PDB format.  
4.4 Docking 
Hex v6.3 
It was written by dave Ritchie. It is an interactive protein docking and molecular superposition 
program. Hex understands protein and DNA structures in PDB format, and it can also read small-
molecule SDF files. 
Protocol 
The pdb files of receptor HDAC proteins and ligands were uploaded on Hex working platform 
and then it followed docking. The binding energy details of proteins were saved in log file and 
structural complex as pdb files. 
4.4 Analysis of Binding sites by LIGPLOT+  
LIGPLOT+ 
It is graphical user interface version of LIGPLOT and DIMPLOT programs. The plots generated 
by these programs can be interactively edited on screen, superposed and printed. 
Protocol 
 The interacting residues of protein and ligand were analyzed using LIGPLOT + software and 
analyzed for best ligand for the HDAC 4, 5, and 7. 
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5. Result and Discussion 
5.1 Interaction of the inhibitor with HDACs 
The docking result obtain by Hex was saved in PDB format to visualize in the LIGPLOT 
software to identify the interacting residues. The residues details are described in the table 1 
below. It has been identified that sulphoraphane interact with the following residues (Glu 221, 
Asp 178, His 155, Zn2+, Asp 132, Ala 332, and Ile 329) of  HDAC 4 (Fig 8). Similarly on 
interaction with HDAC 6 following reduies Asp 71, Zn2+, Ala 46, Phe 45 were identified (Fig 9). 
But it has observed that sulforaphane interact with sites other than the active sites residues. 
HDAC 7 (Fig10) .Thus it can be inferred as HDAC 4 and 6 can be inhibited by sulphoraphane 
while it is unable to inhibit HDAC 7. In case of HDAC 4 and 6 sulforaphane is able to bind to 
Zn2+ ion and one of the amino acid residue of active site (Asp 178 and Asp71 respectively) (fig 8 
nad 9). Due to this reason it may inhibit the enzyme by distressing the Zn2+ ion. Similarly the 
inhibitor “Allyl disulfide” interact with Asp272, Zn2+, Tyr319, Ile329, Glu 328, Asp326 and 
Val323 residues of HDAC 4 (fig 11) while Leu8 and Lue 71 residues in HDAC 6 (fig 12) and 
Asp 285, Arg79,Cys 397,  Met 298 and Ile280 residues were identified in HDAC 7 (fig 13). 
Subsequently on analysis of interaction with inhibitor “Butyrate” following residues were 
identified to be Cys169, Phe168, Asp178, Pro165, Met 166 and Zn2+ in HDAC 4 (fig 14) and 
Ala 46 of HDAC 6 (fig15) and Asp191 and Pro 293 of HDAC 7 (Fig16). Butyrate binds to Zn2+ 
ion and active site residue (Asp 178) of HDAC4 but in case of HDAC 6 and HDAC 7 it unable 
to bind to the active site and Zn2+. Allyl disulfide and butyrate both unable to bind to active site 
and Zn2+ thus cannot inhibit HDAC 6 and HDAC 7  .In all cases the interaction between ligand 
and Zn++ ion is electrostatic interaction where as the interaction between the active site amino 
acid residue and ligand is hydrophobic,van der waals and hydrogen bond. 
Table 1: Active Site residue of HDAC (4, 6, and 7) (Tambunan et al. 2011, (Suppl 13):S23,) 
Enzyme Active site residues 
HDAC 4 Ion Zn2+, Asp193, His195, and Asp287 
HDAC 6 Ion Zn2+, Asp71, His73, and Asp164 
HDAC 7 Ion Zn2+, Asp191, His193, and Asp285 
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Table 1 : Interactions of Sulforaphane, Allyl Disulfide and Butyrate with HDAC 4,6,7
Ligands/Protein HDAC4 
Sulforaphane Glu221, 
Zn2+, Asp132, Ala332, 
Ile329  
Allyl disulfide Asp272, Zn2+, 
Ile329, Glu 328, Asp326, 
Val323 
Butyrate Cys169, Phe168, 
Asp178, Pro165, Met 
166, Zn2+ 
* Residues of active site written in bold letter.
  Fig 8: Interaction between HDAC4 and sulforaphane
                                                                                                       
HDAC6 HDAC7
Asp178, His155, Asp71,  Zn2+,  
Ala 46, Phe45  
 
Arg154
Leu 105 
 
Tyr319, Leu8, Lue 71  
 
Asp 285
Cys 397,  Met 298, Ile280 
 
 
Ala46 Asp191
 
 
      
       Fig 9 Interaction between 
HDAC6 and sulforaphane
 
 
, Gly 36, Leu19, 
 
, Arg79, 
 
,Pro293  
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Fig 10: Interaction between HDAC7 and sulforaphane 
 
Fig 11: Interaction between HDAC4 and allyl disulfide 
 
HDAC 7 and sulforaphane 
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Fig 12: Interaction between HDAC 6 and allyl disulfide
Fig 13: Interaction between HDAC 7 and allyl disulfide
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Fig 14: 
Fig 15: Interaction between HDAC 6
                                                                          
 
Interaction between HDAC4 and butyrate
      
 and butyrate  Fig 16: Interaction between 
                           HDAC 7 and butyrate
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      Fig17: HDAC4 and sulforaphane   Fig18: HDAC6 and sulforaphane 
          
       Fig19: HDAC 4 and Allyl disulfide   Fig20: HDAC 4 and Butyrate 
 
Figs 17-20: Rrepresents the interactions between inhibitors (sulforaphane, Allyl disulfide, 
butyrate) in green color and HDAC (4, 6) in light blue color  
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5.2 Binding Free energy  
The result of the docking are save in log format file. These log files contain the binding energy 
between ligand and protein. The docking result shows that sulforaphane have lowest binding 
energy in case of HDAC4 in comparison to allyl disulfide and butyrate.  
Table2: The binding free energy docking simulation result of Sulforaphane, Butyrate, Allyl 
Disulfide toward HDAC(4,6,7)  
 
Binding Energy, ∆ G (kcal/mole) 
Ligands HDAC 4 HDAC 6 HDAC 7 
Sulforaphane -177.6 -111.9 -157.8 
Allyl disulfide -157.6 -100.6 -132.2 
Butyrate -134.7 -112.4 -145.7 
 
The binding energy of the ligands and protein was plotted in the table 2. The negative binding 
energy shows that the reactions are spontaneous. 
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6. Conclusion 
From above in silco study we can conclude that Sulforaphane shows inhibitory activity towards 
HDAC (4, 6) as it is interacting with the Zn2+ ion of enzyme active site and turn it into inactive 
form. Whereas allyl disulfide and butyrate only able to interact with active site and Zn2+ ion of 
HDAC4. This experiment is only the in silico approach, which need approval after future 
experiments (in vivo). We had tested three inhibitor including, sulforaphane, allyl disulfide and 
butyrate against HDAC 4,6 and 7. If the future experimental results establish that these three 
bioactive compounds have potent in vivo HDAC inhibition property then it will add a new 
dimension in cancer treatment.  
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